Oculis to Ring Nasdaq Stock Market Opening Bell in Celebration of its Successful Listing

Mar 22, 2023

ZUG, Switzerland, and BOSTON, March 22, 2023 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS) ("Oculis"), a global biopharmaceutical company purposefully driven to save sight and improve eye care, announces that it will ring the Nasdaq opening bell today to celebrate its public listing on the Nasdaq Stock Market earlier this month.

Oculis is advancing multiple late clinical-stage product candidates in key areas of medical need. Its highly differentiated pipeline comprises candidates in development including: OCS-01, a topical eye drop candidate for diabetic macular edema (DME); OCS-02, a topical eye drop biologic candidate for dry eye disease (DED); and OCS-05, a disease modifying candidate for acute optic neuritis (AON) and other neuro-ophtha disorders such as glaucoma.

To advance its mission and deliver upcoming near-term clinical milestones, Oculis is privileged to have the support of leading institutional healthcare investors including funds managed by LSP, Earlybird, Novartis Venture Fund, Tekla Capital Management LLC, Pivotal Life Sciences, and VI Partners, among others.

Riad Sherif MD, Chief Executive Officer of Oculis, will be joined by other members of Oculis' executive team, Board of Directors, Scientific Advisory Board members and guests, at the ceremony, which will begin at approximately 9.15am EDT and can be viewed live at https://www.nasdaq.com/marketsite/bell-ringing-ceremony and on the Nasdaq MarketSite Tower in New York. The Nasdaq opening bell ringing will take place at 9:30am EDT, signifying the start of the day's trading session.

Riad Sherif MD, CEO of Oculis, commented: *"We are ringing the opening bell today in celebration of Oculis' public listing, which would not have been possible without the great support of our investors, our partners and the dedication of our employees. Listing on Nasdaq is a major corporate milestone, providing Oculis a robust financial position that enables the advancement of several clinical programs addressing medical needs in ophthalmology, including retina, dry eye, and neuro-ophtha diseases such as acute optic neuritis and glaucoma. We have recently achieved last-patient-last-visit in Stage 1 Phase 3 DIAMOND study of OCS-01 eye drop in diabetic macular edema, and results from this Stage 1 are expected shortly. We also recently completed enrollment in OCS-01 Phase 3 OPTIMIZE study for the treatment of inflammation and pain following cataract surgery, and results from this trial are expected later this year."*

Anthony Rosenberg, Chairman of Oculis' Board of Directors, commented *: "I would like to congratulate the entire team on the successful completion of the business combination and Oculis' entry on the Nasdaq Stock Market. I would also like to welcome my new colleagues who have joined the Company's Board of Directors, and to thank my former Board colleagues for all their great work and accomplishments to date. I look forward to working with the new Board and the wider Oculis team on bringing innovative ophthalmic therapies for patients and generating value for shareholders."*

-ENDS-

About Oculis

Oculis is a global biopharmaceutical company (Nasdaq: OCS) purposefully driven to save sight and improve eye care. Oculis' highly differentiated pipeline comprises multiple innovative product candidates in development. It includes OCS-01, a topical eye drop retinal candidate for diabetic macular edema (DME); OCS-02, a topical eye drop biologic candidate for dry eye disease (DED); and OCS-05, a disease modifying candidate for acute optic neuritis (AON) and other neuro-ophtha disorders such as glaucoma, diabetic retinopathy, geographic atrophy, and neurotrophic keratitis. Headquartered in Switzerland and with operations in the US, Europe, and China, Oculis' goal is to deliver life-changing treatments to patients worldwide. The company is led by an experienced management team with a successful track record and is supported by leading international healthcare investors.

For more information, please visit: www.oculis.com

Contacts

Investor Relations

Dr Riad Sherif, CEO
riad.sherif@oculis.com

Mrs Sylvia Cheung, CFO
sylvia.cheung@oculis.com

Media Relations

Consilium Strategic Communications
Amber Fennell, Tracy Cheung, David Daley

oculis@consilium-comms.com

Cautionary Statement Regarding Forward Looking Statements

This press release contains forward looking statements and information. For example, statements regarding expected future milestones and catalysts; the initiation, timing, progress and results of Oculis' clinical and preclinical studies; Oculis' research and development programs, regulatory and business strategy, future development plans, and management; Oculis' ability to advance product candidates into, and successfully complete, clinical trials; and the timing or likelihood of regulatory filings and approvals, are forward looking. All forward looking statements are based on estimates and assumptions that, while considered reasonable by Oculis and its management, are inherently uncertain and are inherently subject to risks, variability and contingencies, many of which are beyond Oculis' control. These forward-looking statements are provided for illustrative purposes only and are not intended to serve as, and must not be relied on by an investor as, a guarantee, assurance, prediction or definitive statement of a fact or probability. Actual events and circumstances are difficult or impossible to predict and will differ from assumptions. All forward-looking statements are subject to risks, uncertainties and other factors that may cause actual results to differ materially from those that we expected and/or those expressed or implied

by such forward-looking statements. Forward-looking statements are subject to numerous conditions, many of which are beyond the control of Oculis, including those set forth in the Risk Factors section of Oculis' proxy statement and the prospectus for Oculis' offering, and any other documents filed with the U.S. Securities and Exchange Commission (the "SEC"). Copies of these documents are available on the SEC's website, www.sec.gov. Oculis undertakes no obligation to update these statements for revisions or changes after the date of this release, except as required by law.